Neoadjuvant Nivolumab Safe, Led to Major Response Rates in Resectable Lung Cancer

Cancer,Volume 124, Issue 16, Page 3283-3283, August 2018.

Source: Cancer - August 24, 2018 Category: Cancer & Oncology Source Type: research